Abiomed, Inc. Earnings Conference Call (Q2 2010)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Nov 5 Calls Today's Calls

Call Details Abiomed, Inc. Earnings Conference Call (Q2 2010) Thu, Nov 5, 2009, 8:00 am Eastern Listen to the archived event audio About Abiomed, Inc. (NasdaqGM:ABMD) Abiomed, Inc. and its subsidiaries manufacture and sell medical devices in circulatory support that offer a continuum of care in heart recovery to acute heart failure patients. It offers various disposable products for the surgery suite, which comprise BVS 5000 blood pump and AB5000 ventricle for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis; integrated cannula system that connects the ventricle or blood pump to the heart and an associated artery; and Impella LD that provides temporary left ventricular assist devices support for recovery from post-cardiotomy hemodynamic instability and cardiogenic shock. The company also provides disposable products for the cardiac catheterization lab and the surgery suite that include Impella 2.5 and 5.0 catheters, which are percutaneous micro heart pumps with integrated motors and sensors for use in interventional cardiology and heart surgery; and IAB, a percutaneous intra-aortic balloon used to support various prophylactic, pre-shock, and profound shock conditions. In addition, it offers driver console products, such as AB5000 console for BVS 5000 blood pump and AB5000 ventricle; mobile pump consoles for Impella products; iPulse console, a multi-purpose driver console for IAB, AB5000, BVS 5000, and other manufacturers’ IABs; and portable discharge driver for AB5000 for in-hospital and out-of-hospital patients. Further, Abiomed provides AbioCor implantable replacement heart, a self-contained artificial heart for severe biventricular heart failure. It sells its products through direct sales representatives and clinical support personnel in the United States, Germany, France, the United Kingdom, and Ireland; and internationally. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings